First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis
What Changed
- First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
- BlackRock reports sole voting power over 2.5M First Tracks (TRAX) shares in an amended stake report.
- First Tracks Biotherapeutics Announces $200 Million Private Placement
Price Move History
- Daily moves over 5%
- 47 134 sessions, April 20, 2026 to October 28, 2026
- Largest daily move
- +56% close of July 9, 2026
- 1-month change
- +24.8% closing prices, September 28, 2026 to October 28, 2026
Company Description
First Tracks Biotherapeutics (NASDAQ: TRAX) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $1.9B.
TRAX has gained 24.8% over the past month. The last closing price was $45.72.
This page collects what Stock Titan holds for TRAX, including price data, latest news, SEC filings, insider trading activity, upcoming events, and short interest trends.
Stock Performance
First Tracks Biotherapeutics (TRAX) closed at $45.72 on October 28, 2026. Over the past month, the price has gained 24.8%.
TRAX Metrics & Rankings
Price returns through October 28, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
First Tracks Biotherapeutics has 8 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 2 with negative movement. Key topics include private placement, clinical trial, earnings, conferences. View all TRAX news →
SEC Filings
First Tracks Biotherapeutics has filed 10 recent SEC filings, including 4 Form 4, 3 Form 8-K, 1 Form 144, 1 Form SCHEDULE 13G/A. The most recent filing was submitted on October 27, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all TRAX SEC filings →
Insider Radar
Insider selling at First Tracks Biotherapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Upcoming Events
Late-stage trial start
Cohort 2 top-line readout
ANB033 Cohort 2 Data
ANB033 EoE top-line data
EoE Phase 1b Topline
First Tracks Biotherapeutics has 5 upcoming scheduled events. The next event, "Late-stage trial start", is scheduled for January 1, 2027 (in 64 days). Investors can track these dates to stay informed about potential catalysts that may affect the TRAX stock price.
Short Interest History
Short interest in First Tracks Biotherapeutics (TRAX) currently stands at 5.2 million shares, up 15.3% from the previous reporting period, representing 15.8% of the float. Since April 2026, short interest has increased by 28.8%.
Days to Cover History
Days to cover for First Tracks Biotherapeutics (TRAX) currently stands at 6.2 days, down 17.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 4.2 to 10.4 days.
TRAX Company Profile & Sector Positioning
First Tracks Biotherapeutics (TRAX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.